Expert Consensus Recommendations* for the Pharmacological Management of Attention Deficit, Hyperactivity, and Impulsivity in Phelan-McDermid Syndrome

Diagnostic assessment

Medical causes (e.g., sleep, epilepsy, infectious, gastrointestinal, metabolic)?

Yes → Treat/refer for treatment

No → Other neuropsychiatric causes (e.g., anxiety, sensory-seeking behaviors)?

Yes → Treat/refer to specialist/refer to specific algorithms

No → Improvement?

Yes → Follow up as needed

No → Continuation/Maintenance

Increase as tolerated; consider extended release

Partial response or nonresponse → *Guanficine, clonidine

Response → Continuation/Maintenance

Partial or nonresponse → *Methylphenidate, amphetamine

Response → Continuation/Maintenance

Increase as tolerated; consider extended release; monitor for agitation/mania

Partial response or nonresponse → Combined treatment: stimulant + alpha agonist

Response → Continuation/Maintenance

Partial or nonresponse → Viloxazine, atomoxetine (if patient can swallow pills whole)

Response → Continuation/Maintenance

Partial or nonresponse → Antipsychotics +/- stimulant, alpha agonist, atomoxetine

Nonresponse → Clinical Consultation

Partial or nonresponse (in severe cases)

*These recommendations are not established as “evidence-based.”
Expert Consensus Recommendations* for the Pharmacological Management of Irritability and Aggression in Phelan-McDermid Syndrome

Diagnostic assessment

Medical causes (e.g., epilepsy, infectious, gastrointestinal, metabolic, pulmonary)?

No

Other neuropsychiatric causes (anxiety can cause aggression)

Rule out catatonia

Yes

Treat/refer for treatment

Improvement?

Yes

Follow up as needed

No

Treat/refer to specialist/refer to specific algorithms

Consider

Increase as tolerated; consider extended release

Partial response or nonresponse

Response

Continuation/Maintenance

Partial response (augment) or nonresponse (cross-titrate)

Risperidone, aripiprazole, quetiapine (and XR), olanzapine

Response

Continuation/Maintenance

Increase as tolerated

Partial response or nonresponse

Response

Continuation/Maintenance

Partial response (augment) or nonresponse (cross-titrate)

Divalproex sodium, lamotrigine, carbamazepine, oxcarbazepine, lithium

Response

Continuation/Maintenance

Increase as tolerated; consider combined treatment

Partial response or nonresponse

Response

Continuation/Maintenance

Partial response (augment) or nonresponse (cross-titrate)

Benzodiazepines, gabapentin, antihistamines, baclofen, propranolol, CBD

Response

Continuation/Maintenance

Increase as tolerated; consider combined treatment

Partial response or nonresponse

Response

Continuation/Maintenance

Partial response (augment) or nonresponse (cross-titrate)

Chlorpromazine, perphenazine, clozapine

Nonresponse

Clinical Consultation

∗These recommendations are not established as “evidence-based.”
Expert Consensus Recommendations* for the Pharmacological Management of Anxiety in Phelan-McDermid Syndrome

1. Diagnostic assessment
   - No
   - Medical causes (e.g., epilepsy, infectious, gastrointestinal, metabolic, pulmonary)?
     - Yes
       - Assess environmental triggers; implement routines; ensure adequate sleep hygiene
       - Improvement?
         - Yes
           - Follow up as needed
         - No
           - Neuropsychiatric causes? Be aware that anxiety/OCD symptoms can forewarn bipolar/catatonia
             - Yes
               - Treat/refer to specialist/refer to specific algorithms
             - No
               - Consider

2. Use SSRIs with caution
   - No
   - N-acetylcysteine (up to 2700 mg daily)
     - Partial response or nonresponse
       - Response
         - Continuation/Maintenance
       - Nonresponse
         - Propranolol, buspirone, trazodone
           - Partial response or nonresponse
             - Response
               - Continuation/Maintenance
             - Nonresponse
               - Gabapentin, mirtazapine, TCAs (e.g., clomipramine)
                 - Partial response or nonresponse
                   - Response
                     - Continuation/Maintenance
                   - Nonresponse
                     - Benzodiazepines prn, CBD
                       - Partial response or nonresponse
                         - Response
                           - Continuation/Maintenance
                         - Nonresponse
                           - Antipsychotics (RISP; ARI; QUE; OLZ)
                             - Nonresponse
                               - Clinical Consultation

*These recommendations are not established as “evidence-based.”
Expert Consensus Recommendations* for the Pharmacological Management of Mood Cycling in Phelan-McDermid Syndrome

Diagnostic assessment

- Medical causes (e.g., epilepsy, immunologic, metabolic/thyroid)?
  - Yes: Treat/refer for treatment
  - No: Follow up as needed

- Relationship to menstrual cycle? Consider OCPs
  - Yes: Treat/refer to specialist/refer to specific algorithms
  - No: Consider

- Other neuropsychiatric cause? rule out catatonia

  If urgent/severe, stabilize with second generation antipsychotic (QUE, ARI, RISP)
  If less urgent/severe, start with mood stabilizer (VPA, LI, LAM)

Increase cautiously as tolerated

- Response
- Partial response or nonresponse
- Nonresponse

  Augment with mood stabilizer (VPA, LI, LAM)
  Add benzodiazepine (lorazepam; clonazepam)

Continuation and Maintenance

Partial response or nonresponse

- Response
- Nonresponse

  Add benzodiazepine (lorazepam; clonazepam)

Other neuropsychiatric cause? rule out catatonia

- Yes: Improvement?
  - Yes: Treat/refer to specialist/refer to specific algorithms
  - No: Follow up as needed

- No: Other neuropsychiatric cause? rule out catatonia

Response

Partial response or nonresponse

- Response
- Nonresponse

  Switch antipsychotic (QUE, ARI, OLZ, RISP)

Other neuropsychiatric cause? rule out catatonia

- Yes: Improvement?
  - Yes: Treat/refer to specialist/refer to specific algorithms
  - No: Follow up as needed

- No: Other neuropsychiatric cause? rule out catatonia

Response

Partial response or nonresponse

- Response
- Nonresponse

  Switch mood stabilizer (CBZ, OXC, TOP)

Other neuropsychiatric cause? rule out catatonia

- Yes: Improvement?
  - Yes: Treat/refer to specialist/refer to specific algorithms
  - No: Follow up as needed

- No: Other neuropsychiatric cause? rule out catatonia

Response

Partial response or nonresponse

- Response
- Nonresponse

  ECT

Clinical Consultation

*These recommendations are not established as “evidence-based.”
Expert Consensus Recommendations* for the Pharmacological Management of Sleep Disturbance in Phelan-McDermid Syndrome

Diagnostic assessment

- Medical causes (e.g., epilepsy, infectious, gastrointestinal, metabolic, pulmonary)?
  - No
  - Restless legs? Consider adding iron if ferritin < 50 ug/L
  - Neuropsychiatric causes?

Assess and implement adequate sleep hygiene

Treat/refer for treatment

- Improvement?
  - Yes
  - Follow up as needed
  - No
  - Consider

Treat/refer to specialist/refer to specific algorithms

Increase melatonin up to 10 mg; consider sublingual or extended release

Melatonin (sleep onset)

5HTP (sleep maintenance)

Partial response or nonresponse

- Response
  - Continuation/Maintenance
  - Nonresponse

Clonidine (sleep onset) or trazodone

Partial response or nonresponse

- Response
  - Continuation/Maintenance
  - Nonresponse

Mirtazapine, doxepine

Partial response or nonresponse

- Response
  - Continuation/Maintenance
  - Nonresponse

Quetiapine (and XR)

Partial response or nonresponse

- Response
  - Continuation/Maintenance
  - Nonresponse

Gabapentin, zolpidem, benzodiazepines, amitriptyline, antihistamines

Partial response or nonresponse

- Response
  - Continuation/Maintenance
  - Nonresponse

Restless legs? Consider adding iron if ferritin < 50 ug/L

*These recommendations are not established as “evidence-based.”
Expert Consensus Recommendations* for the Pharmacological Management of Catatonia** in Phelan-McDermid Syndrome

### Diagnostic assessment

- Medical causes (e.g., neuroleptic side effects, epilepsy, infectious, metabolic)?
  - Yes: Treat/refer for treatment
  - No: Other neuropsychiatric causes?
    - Yes: Treat/refer to specialist/refer to specific algorithms
    - No: Consider

### Improvement?

- Yes: Follow up as needed
- No: Proceed to next step

### Benzodiazepines

- Increase cautiously as tolerated (e.g., lorazepam 0.5-8mg TID)
- Partial or Nonresponse
  - Response: Continuation/Maintenance
  - Partial or Nonresponse: Electroconvulsive therapy (ECT) +/- benzodiazepines
    - If ECT not available, consider lithium, VPA, or LAM

### Increase frequency as tolerated

- Partial or Nonresponse
  - Response: Continuation/Maintenance
  - Partial or Nonresponse: ECT maintenance + benzodiazepines
  - Response: Continuation/Maintenance
  - Partial response: ECT maintenance + benzodiazepines
    - Response: Continuation/Maintenance
    - Nonresponse: Clinical Consultation

### Increase ECT frequency and/or dose as tolerated

- Partial or Nonresponse
  - Response: Continuation/Maintenance
  - Partial response: ECT maintenance + benzodiazepines
    - Response: Continuation/Maintenance
    - Nonresponse: Clinical Consultation

### Increase dose as tolerated

- Partial or Nonresponse
  - Response: Continuation/Maintenance
  - Partial response: Clinical Consultation

---

*These recommendations are not established as “evidence-based.”
**Notes for the Treatment Algorithm for the Pharmacological Management of Catatonia in Phelan-McDermid Syndrome**

- Would recommend starting lorazepam 0.5-1 mg TID, and increasing by 0.5 mg TID every few days, based on response.
- Track frequency of catatonia symptoms objectively to carefully guide titration; increase lorazepam until symptom improvement plateaus, or until the point of over-sedation.
- Monitor vital signs closely and if unstable, expedite to urgent referral for ECT.
- If no response to benzodiazepines, ECT alone is the next step assuming symptom severity warrants it. If the patient is simply prompt dependent with psychomotor retardation, ECT may not be indicated.
- If only PARTIAL response to benzodiazepines, consider ECT while remaining on the benzodiazepine, and using flumazenil reversal. It is NOT necessary to taper the benzodiazepine.
- If there is PARTIAL response to benzodiazepines, and the remaining symptoms do not warrant ECT, consider adjunctive antidepressant or mood stabilizer, depending on the underlying psychopathology.
- Acute ECT needs to be delivered at least three times weekly with BILATERAL electrode placement and monitoring for seizure quality.
- If inadequate response to bilateral ECT, consult with an expert to address ECT technical parameters and associated medications to improve seizure quality.
- Every patient who responds to ECT requires medication to decrease maintenance ECT frequency while maintaining clinical stability.
- Once the patient is on twice weekly ECT, start lithium and titrate to a therapeutic serum level as you decrease ECT frequency.
Any person with PMS who is in their usual state of health and experiences the onset of at least three of the following symptoms according to the Diagnostic and Statistical Manual for Mental Disorders Fifth Edition (DSM-5, APA, 2013):

1. Stupor (i.e., no psychomotor activity; not actively relating to environment);
2. Catalepsy (i.e., passive induction of a posture held against gravity);
3. Waxy flexibility (i.e., slight, even resistance to positioning by examiner);
4. Mutism (i.e., no, or very little, verbal response);
5. Negativism (i.e., opposition or no response to instructions or external stimuli);
6. Posturing (i.e., spontaneous and active maintenance of a posture against gravity);
7. Mannerisms (i.e., odd, circumstantial caricature of normal actions);
8. Stereotypy (i.e., repetitive, abnormally frequent, non-goal-directed movements);
9. Agitation, not influenced by external stimuli;
10. Grimacing;
11. Echolalia (i.e., mimicking another’s speech);
12. Echopraxia (i.e., mimicking another’s movements)

*The Diagnostic Manual - Intellectual Disability, Second Edition (DM-ID2; Barnhill et al., 2017) notes that mutism, mannerisms, stereotypies, and grimacing can also be features of intellectual disability, and that echolalia can be a feature of ASD, so the history and time of onset of these symptoms is critical to delineate.
Clinical Guidelines to Initiate a Laboratory-Based Assessment to rule out Encephalitis in Phelan-McDermid Syndrome

Presence of encephalopathy defined as:
(1) depressed of altered level of consciousness lasting 24 hours OR
(2) lethargy OR
(3) personality change

PLUS at least 1 of the following:
(a) fever;
(b) seizure;
(c) focal neurological findings;
(d) CSF pleocytosis;
(e) EEG or neuroimaging findings “consistent with encephalitis”

Any person with PMS who is in their usual state of health and experiences the onset of several of the following symptoms accompanied by new focal neurological signs, or in the absence of focal neurological signs, any person whose psychiatric symptoms fail to respond to appropriate trials of psychiatric medications may warrant a work-up to exclude encephalitis:

-A marked change in sleep patterns;
-Symptoms characteristic of mania or depression;
-New, intense anxiety (obsessive compulsive symptoms, separation anxiety, phobias);
-Loss of previous abilities; general confusion; disorientation;
-New and unusual motor patterns, such as changes in gait, difficulty making transitions across visual borders, and loss of hand skills;
-New incontinence;
-Note that multiple recurrent episodes may occur.
Blood Tests:
Comprehensive metabolic panel (CMP)
Complete blood count (CBC) and Differential
Serum Iron, Total Iron Binding Capacity (TIBC), Iron saturation
Erythrocyte sedimentation rate (ESR)
C-reactive protein (CRP)
Vitamin B12 level
Vitamin B6 level
Vitamin D level
Folate level
Free T4 and Thyroid Stimulating Hormone
Serum homocysteine, total
Celiac serology
Fluorescent ANA
Strep titer - if not done in the past three months or history of recurrent strep throats
Anti-thyroid antibodies: Thyroglobulin Ab and Thyroid Peroxidase (TPO) Ab

Serum Autoimmune Encephalopathy Evaluation (profile + reflex tests)

Cerebral spinal fluid studies using lumbar puncture are recommended if the patient has:
(1) seizures; (2) no response to standard treatment of catatonia; (3) new onset movement disorder (e.g., choreiform movements)

Cerebral Spinal Fluid Studies:
Neopterin (HPLC Fluorescence)
Serum and CSF: IgG, albumin, Oligo bands (Mayo Clinic Multiple Sclerosis Panel)
Routine CSF measures: gram stain, culture cell counts, glucose, and protein
Spinal Autoimmune Encephalopathy Evaluation (profile + reflex tests)

Other studies:
Brain MRI with or without contrast (must be done prior to lumbar puncture)
Electroencephalogram (EEG) - overnight if possible or extended if indicated. Routine EEG Is adequate if clinical suspicion is low and there is no evidence of clinical seizures

Mayo Clinic Laboratories - https://www.mayocliniclabs.com/
MNG Laboratories - https://mnglabs.com/
If any evidence of CNS infection, follow standard of care procedures
Useful References


